Pelka K, De Nardo D. Emerging Concepts in Innate Immunity. Methods Mol Biol. 2018;1714:1-18. doi:10.1007/978-1-4939-7519-8_1
Aneichyk T, Hendriks WT, Yadav R, et al. Dissecting the Causal Mechanism of X-Linked Dystonia-Parkinsonism by Integrating Genome and Transcriptome Assembly. Cell. 2018;172(5):897-909.e21. doi:10.1016/j.cell.2018.02.011
Marshall JL, Doughty BR, Subramanian V, et al. HyPR-seq: Single-cell quantification of chosen RNAs via hybridization and sequencing of DNA probes. Proc Natl Acad Sci U S A. 2020;117(52):33404-33413. doi:10.1073/pnas.2010738117
Ma Y, Walsh MJ, Bernhardt K, et al. CRISPR/Cas9 Screens Reveal Epstein-Barr Virus-Transformed B Cell Host Dependency Factors. Cell Host Microbe. 2017;21(5):580-591.e7. doi:10.1016/j.chom.2017.04.005
Lucas D, O’Leary HA, Ebert BL, Cowan CA, Tremblay CS. Utility of CRISPR/Cas9 systems in hematology research. Exp Hematol. 2017;54:1-3. doi:10.1016/j.exphem.2017.06.006
Kanarek N, Keys HR, Cantor JR, et al. Histidine catabolism is a major determinant of methotrexate sensitivity. Nature. 2018;559(7715):632-636. doi:10.1038/s41586-018-0316-7
Xu YX, Redon V, Yu H, et al. Role of angiopoietin-like 3 (ANGPTL3) in regulating plasma level of low-density lipoprotein cholesterol. Atherosclerosis. 2018;268:196-206. doi:10.1016/j.atherosclerosis.2017.08.031
Hu JH, Miller SM, Geurts MH, et al. Evolved Cas9 variants with broad PAM compatibility and high DNA specificity. Nature. 2018;556(7699):57-63. doi:10.1038/nature26155
Manguso RT, Pope HW, Zimmer MD, et al. In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target. Nature. 2017;547(7664):413-418. doi:10.1038/nature23270
Lane-Reticker SK, Manguso RT, Haining N. Pooled in vivo screens for cancer immunotherapy target discovery. Immunotherapy. 2018;10(3):167-170. doi:10.2217/imt-2017-0164